- Home
- NCV vs RCKT Comparison
NCV vs RCKT Comparison
Compare NCV & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCV | RCKT |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.7M | 401.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NCV | RCKT |
|---|---|---|
| Price | $17.08 | $3.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 80.0K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.31 | $2.19 |
| 52 Week High | $17.53 | $5.45 |
Technical Indicators
Market Signals| Indicator | NCV | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 39.28 |
| Support Level | $14.67 | $3.02 |
| Resistance Level | $17.53 | $3.52 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 49.53 | 25.69 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.